Teva Wins FDA Nod For DEGEVMA, Completing Denosumab Portfolio

With FDA approval of DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab), Teva Pharmaceutical has closed the loop on a two-product denosumab strategy that now spans both oncology bone disease and osteoporosis indications, a portfolio architecture that will draw close attention from regulatory affairs teams tracking biosimilar approval pathways in complex biologics.

DEGEVMA is approved across all Xgeva® reference indications: prevention of skeletal-related events in adults with bone-metastatic advanced cancer, treatment of giant cell tumor of bone in adults and skeletally mature adolescents, and treatment of hypercalcemia of malignancy. The approval rests on a totality-of-evidence package demonstrating no clinically meaningful differences from the reference product in safety, purity, and potency, the standard analytical and clinical comparability framework regulators apply under 21 CFR Part 601 biosimilar guidance.

DEGEVMA is Teva's second FDA biosimilar approval in 2026. The first, PONLIMSI™ (denosumab-adet), received clearance in March 2026 and covers Prolia® indications, primarily osteoporosis. Together, the two products share the same INN qualifier suffix (-adet), reflecting shared molecular lineage and Teva's in-house biologics development infrastructure. For QA and technical operations leads, the dual-suffix strategy signals a manufacturing platform capable of supporting differentiated regulatory submissions from a single biologic molecule.

Teva's regulatory submission for DEGEVMA included analytical, clinical, and immunogenicity data. The molecule is a human monoclonal antibody targeting RANKL, an essential regulator of osteoclast formation and survival; inhibition reduces bone resorption and cancer-induced bone destruction. DEGEVMA already holds approval in the European Union, meaning Teva's CMC and quality dossiers have cleared two major regulatory jurisdictions, a data point relevant to manufacturers benchmarking their own global biosimilar submission strategies.

U.S. commercial launch for both DEGEVMA and PONLIMSI is anticipated in the coming months. Plant heads and supply chain leads should note that launch sequencing across two biosimilars with shared manufacturing origins will test batch scheduling, serialization readiness, and distribution network capacity simultaneously.

The measurable outcome to watch is market uptake against Amgen's reference products in the oncology bone disease segment, where biosimilar penetration rates will serve as a leading indicator of whether Teva's dual-portfolio approach translates into sustained volume.

Source: Teva Pharmaceutical Industries Ltd. via GlobeNewswire, September 28, 2026.